Dustin Samples

Cancer Nursing Today nonprod

In an abstract presented at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO), Houston, Texas, Lazar Chadievski, MD, University Clinic for Hematology, Skopje, Macedonia, presented the results of a comparative analysis study evaluating the effects of anti-thymocyte globulin (ATG) on in vivo T cell depletion in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplant (HSCT). The researchers hoped that ATG would significantly decrease the risk of graft-versus-host disease (GVHD) after HSCT.The researchers retrospectively analyzed the results of 40 patients with AML who underwent allogeneic HSCT between 2014 and 2021, comparing the outcomes of patients treated with ATG to those who did not receive ATG (numbers not specified).According to Dr. Chadievski, the incidence of acute GVHD, chronic GVHD, and grade III-IV acute GVHD were significantly higher in the non-ATG group (29% vs 15.8%, 24% vs 15.8%, and 19% vs 10%, respectively). Similarly, the relapse rates were higher in the non-ATG group (19% vs 16%).The research team observed no differences between the 2 groups in overall survival.Based on the study&rsquo;s results, the authors concluded, &ldquo;Using ATG in the conditioning of patients with AML undergoing allogeneic HSCT for in vivo T-cell depletion is justified as it leads to lower rates of GvHD and better quality of life without worsening relapse rates while maintaining the curative potential of allogeneic HSCT.&rdquo;ReferenceChadievski L, Veljanovska AP, Stojanovska S, et al. The Efficacy of Anti-Thymocyte Globulin for in Vivo T Cell Depletion in Conditioning in Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation From Related and Unrelated Donors. Abstract AML-325. Presented at the 11th Annual Meeting of the Society of Hematologic Oncology; September 6-9, 2023; Houston, Texas.

GVHD Prophylaxis With Anti-Thymocyte Globulin Decreases Acute and Chronic Incidence

Conferences

The incidence of grade III-IV GVHD was reduced in the cohort who received ATG as well. 

GVHD Prophylaxis With Anti-Thymocyte Globulin Decreases Acute and Chronic Incidence 

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe